KR100359397B1 - 엔도텔린의 활성을 조절하는 비페닐설폰아미드 및 이의 유도체 - Google Patents

엔도텔린의 활성을 조절하는 비페닐설폰아미드 및 이의 유도체 Download PDF

Info

Publication number
KR100359397B1
KR100359397B1 KR1019997007068A KR19997007068A KR100359397B1 KR 100359397 B1 KR100359397 B1 KR 100359397B1 KR 1019997007068 A KR1019997007068 A KR 1019997007068A KR 19997007068 A KR19997007068 A KR 19997007068A KR 100359397 B1 KR100359397 B1 KR 100359397B1
Authority
KR
South Korea
Prior art keywords
isoxazolyl
bromo
mmol
methyl
sulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019997007068A
Other languages
English (en)
Korean (ko)
Inventor
챤밍화이
라주보레고우다
코이스아담
베너에릭조엘
우쳉데
카스틸로로자리오실버스트레
얄라모리벤카타찰라파티
발라지비투쿠디나라야나이옌가
Original Assignee
텍사스 바이오테크놀로지 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27411089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100359397(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/477,223 external-priority patent/US5594021A/en
Application filed by 텍사스 바이오테크놀로지 코포레이션 filed Critical 텍사스 바이오테크놀로지 코포레이션
Application granted granted Critical
Publication of KR100359397B1 publication Critical patent/KR100359397B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1019997007068A 1995-04-04 1996-04-04 엔도텔린의 활성을 조절하는 비페닐설폰아미드 및 이의 유도체 Expired - Fee Related KR100359397B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41619995A 1995-04-04 1995-04-04
US41707595A 1995-04-04 1995-04-04
US08/416,199 1995-04-04
US08/417,075 1995-04-04
US08/477,223 US5594021A (en) 1993-05-20 1995-06-06 Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US08/477,223 1995-06-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1019970707078A Division KR100359396B1 (ko) 1995-04-04 1996-04-04 엔도텔린의활성을조절하는티에닐-,푸릴-및피롤릴설폰아미드및이의유도체

Publications (1)

Publication Number Publication Date
KR100359397B1 true KR100359397B1 (ko) 2002-11-01

Family

ID=27411089

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019997007068A Expired - Fee Related KR100359397B1 (ko) 1995-04-04 1996-04-04 엔도텔린의 활성을 조절하는 비페닐설폰아미드 및 이의 유도체
KR1019970707078A Expired - Fee Related KR100359396B1 (ko) 1995-04-04 1996-04-04 엔도텔린의활성을조절하는티에닐-,푸릴-및피롤릴설폰아미드및이의유도체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019970707078A Expired - Fee Related KR100359396B1 (ko) 1995-04-04 1996-04-04 엔도텔린의활성을조절하는티에닐-,푸릴-및피롤릴설폰아미드및이의유도체

Country Status (24)

Country Link
EP (2) EP0819125B1 (enExample)
JP (3) JP3233642B2 (enExample)
KR (2) KR100359397B1 (enExample)
CN (1) CN1130355C (enExample)
AT (1) ATE243203T1 (enExample)
AU (1) AU711968B2 (enExample)
CA (1) CA2217169C (enExample)
CZ (1) CZ299246B6 (enExample)
DE (2) DE122006000068I1 (enExample)
DK (1) DK0819125T3 (enExample)
EA (2) EA199900808A1 (enExample)
EE (1) EE9700251A (enExample)
ES (1) ES2201181T3 (enExample)
FI (1) FI973879A0 (enExample)
HU (1) HUP9802034A3 (enExample)
NL (1) NL300251I2 (enExample)
NO (1) NO315607B1 (enExample)
NZ (2) NZ306734A (enExample)
OA (1) OA10621A (enExample)
PL (1) PL186854B1 (enExample)
PT (1) PT819125E (enExample)
TR (1) TR199701096T1 (enExample)
TW (1) TW492966B (enExample)
WO (1) WO1996031492A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
SG87053A1 (en) 1996-02-20 2002-03-19 Bristol Myers Squibb Co High melt polymorth of the compound n-(3,4-dimethyl-5-isoxazolyl)-4'- (2-oxazolyl) [1,1'-biphenyl]-2-sulfonamide
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU749167B2 (en) * 1997-04-28 2002-06-20 Encysive Pharmaceuticals Inc. Sulfonamides for treatment of endothelin-mediated disorders
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
GB9803228D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
ATE416772T1 (de) * 1998-07-06 2008-12-15 Bristol Myers Squibb Co Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
ATE309206T1 (de) 1998-07-08 2005-11-15 Sanofi Aventis Deutschland Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
CA2380990A1 (en) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. Substituted aromatic-ring compounds, process for producing the same, and use
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
EP1533311B1 (en) * 1999-12-31 2007-04-25 Encysive Pharmaceuticals, Inc Sulfonamides and derivatives thereof that modulate the activity of endothelin
WO2001049289A1 (en) * 1999-12-31 2001-07-12 Texas Biotechnology Corporation Pharmaceutical and veterinary uses of endothelin antagonists
AU2464301A (en) * 1999-12-31 2001-07-16 Encysive Pharmaceuticals Inc. Sulfonamides and derivatives thereof that modulate the activity of endothelin
GB0000625D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
ATE478857T1 (de) * 2000-09-18 2010-09-15 Toa Eiyo Ltd N-substituierte benzothiophensulfonamid-derivate
US7071220B2 (en) 2000-09-18 2006-07-04 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
EP1347051A4 (en) * 2000-12-26 2004-05-26 Genox Research Inc METHOD FOR EXAMINING AN ALLERGIC DISEASE
CA2479353C (en) * 2002-03-15 2010-09-14 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivative
JP4335136B2 (ja) 2002-08-09 2009-09-30 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
WO2004014851A2 (en) 2002-08-09 2004-02-19 Merck & Co., Inc. Tyrosine kinase inhibitors
SE0301888D0 (sv) * 2003-06-25 2003-06-25 Biovitrum Ab New use VII
SE0301886D0 (sv) * 2003-06-25 2003-06-25 Biovitrum Ab New use V
SE0301883D0 (sv) * 2003-06-25 2003-06-25 Biovitrum Ab New use II
SE0301885D0 (sv) * 2003-06-25 2003-06-25 Biovitrum Ab New use IV
SE0301882D0 (sv) * 2003-06-25 2003-06-25 Biovitrum Ab New use I
SE0301884D0 (sv) * 2003-06-25 2003-06-25 Biovitrum Ab New use III
JP5193602B2 (ja) * 2004-10-14 2013-05-08 アボット ゲーエムベーハー ウント カンパニー カーゲー ドーパミンｄ３受容体の調節に応答する障害の治療に好適なアリールスルホニルメチルまたはアリールスルホンアミド置換芳香族化合物
WO2008124803A1 (en) 2007-04-10 2008-10-16 Auspex Pharmaceuticals, Inc. Substituted deuterium enriched thiophenes for the treatment of hypertension
EP3150589A1 (en) 2007-06-08 2017-04-05 MannKind Corporation Ire-1a inhibitors
ES2651293T3 (es) 2012-01-31 2018-01-25 Eisai R&D Management Co., Ltd. Derivado de sitaxentán
CN107652246B (zh) * 2017-09-25 2020-08-25 江苏乾元生物科技有限公司 一种3-[3-溴-2-甲基-6-(甲基磺酰基)苯基]-4,5-二氢化异噁唑的制备方法
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
JP7352662B2 (ja) 2019-06-18 2023-09-28 ファイザー・インク ベンゾイソオキサゾールスルホンアミド誘導体
EP3831940A1 (en) * 2019-12-05 2021-06-09 Danmarks Tekniske Universitet Small molecule inhibitors of crispr-cas associated activity
CN112663077B (zh) * 2021-01-11 2022-07-01 陕西师范大学 一种苯并磺内酰胺类化合物的电化学制备方法
JP7531947B2 (ja) 2021-06-22 2024-08-13 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤及び医薬組成物
AU2022306778A1 (en) 2021-07-09 2024-01-18 Vicore Pharma Ab New selective angiotensin ii compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660383A (en) * 1968-08-14 1972-05-02 Shionogi & Co Production of iodoisoxazole compounds
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
TW224462B (enExample) * 1992-02-24 1994-06-01 Squibb & Sons Inc
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
IL116916A (en) * 1995-02-06 2000-09-28 Bristol Myers Squibb Co Substituted biphenyl sulfonamide derivatives and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
OA10621A (en) 2001-03-16
PL322707A1 (en) 1998-02-16
CA2217169A1 (en) 1996-10-10
CA2217169C (en) 2005-03-29
AU711968B2 (en) 1999-10-28
EA199900808A1 (ru) 2000-06-26
DE69628740T2 (de) 2004-05-13
CN1184470A (zh) 1998-06-10
JP2002030075A (ja) 2002-01-29
JPH11507015A (ja) 1999-06-22
DE69628740D1 (de) 2003-07-24
HK1001769A1 (en) 1998-07-10
CZ311697A3 (cs) 1998-09-16
TR199701096T1 (xx) 1998-02-21
CN1130355C (zh) 2003-12-10
NO974577L (no) 1997-12-04
AU5536796A (en) 1996-10-23
JP3527217B2 (ja) 2004-05-17
PT819125E (pt) 2003-11-28
EP1048657A1 (en) 2000-11-02
NO974577D0 (no) 1997-10-03
CZ299246B6 (cs) 2008-05-28
TW492966B (en) 2002-07-01
NZ306734A (enExample) 2000-01-28
NL300251I1 (nl) 2007-02-01
EA007107B1 (ru) 2006-06-30
NZ500282A (en) 2000-01-28
FI973879A0 (fi) 1997-10-03
EP0819125B1 (en) 2003-06-18
DK0819125T3 (da) 2003-10-13
KR100359396B1 (ko) 2003-03-15
HUP9802034A2 (hu) 2000-03-28
WO1996031492A1 (en) 1996-10-10
NO315607B1 (no) 2003-09-29
HUP9802034A3 (en) 2000-04-28
NL300251I2 (nl) 2007-03-01
JP2004043495A (ja) 2004-02-12
EP0819125A1 (en) 1998-01-21
EA199700208A1 (ru) 1998-08-27
JP3233642B2 (ja) 2001-11-26
ATE243203T1 (de) 2003-07-15
EE9700251A (et) 1998-04-15
PL186854B1 (pl) 2004-03-31
DE122006000068I1 (de) 2007-05-10
ES2201181T3 (es) 2004-03-16
KR19980703679A (ko) 1998-12-05

Similar Documents

Publication Publication Date Title
KR100359397B1 (ko) 엔도텔린의 활성을 조절하는 비페닐설폰아미드 및 이의 유도체
US6331637B1 (en) N-Alkyl, N-Alkenyl, N-Alkynyl, N-Aryl and N-fused bicyclo or tricyclo thienyl-, furyl-,and Pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
KR100527620B1 (ko) 소수성 유리 설폰아미드의 알칼리 금속 염의 제조방법
US5594021A (en) Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
EP0980369B1 (en) Sulfonamides for treatment of endothelin-mediated disorders
EP0699191B1 (en) Sulfonamides and derivatives thereof that modulate the activity of endothelin
US6613804B2 (en) Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6342610B2 (en) N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
CA2420614A1 (en) Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
HK1032393A (en) Thienyl-, furyl-, pyrrolyl-and biphenylsulfonamides and derivatives thereof that modulate activity of endothelin

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 7

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

Fee payment year number: 8

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20100930

Year of fee payment: 9

PR1001 Payment of annual fee

Fee payment year number: 9

St.27 status event code: A-4-4-U10-U11-oth-PR1001

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20111022

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20111022

St.27 status event code: N-4-6-H10-H13-oth-PC1903